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leading cause of cancer-related death worldwide, is projected to
become the second leading cause by 2030 [1]. In addition to its high
metastatic capacity, this extremely aggressive malignancy is character-
ized by its inherent resistance to chemotherapy and radiotherapy [3].
These attributes are believed to be due to the existence of a subpopula-
tion of stem-like cells within the tumor known as cancer stem cells
(CSCs). CSCs constitute a biologically unique subset of rare cells within
the bulk tumor cell population that possess, by deﬁnition, inherent
self-renewal properties, multipotency and an exclusive ability to initiate
and recapitulate the parental tumor upon serial passage in immunode-
ﬁcient mice [2]. In addition, CSCs participate in the multistep process of
oncogenesis, giving rise to the clonogenic core of the tumor, and these
cells are also necessary for long-term tumor maintenance, are key
drivers of metastasis, and represent the underlying cause of chemo-
and radio-resistance [3].
Reversing CSC-mediated chemo- and radio-resistance would greatly
improve overall patient survival; however, to date, we are still far from
understanding the complex process of therapy resistance. In
EBioMedicine, Chen et al. build upon their previous ﬁndings [4], and
show in this new study that radiotherapy-induced dying tumor cells
not only secrete the high-mobility group box 1 (HMGB1) protein, an ex-
tracellular damage-associatedmolecular patternmolecule, but secreted
HMGB1 can bind to Toll-like receptor 2 (TLR2) on pancreatic CD133+
CSCs to promote their self-renewal and tumorigenic capacity [5]. Thus,
the authors proposeHGMB1 as a previously unrecognized driver of pan-
creatic CSC proliferation in the presence of radiotherapy. Interestingly,
while HMGB1 has been extensively studied in PDAC, its role as a
tumor suppressor or tumor promoter has been debated [8]. For exam-
ple, Kang et al. recently showed that intracellular HMGB1 can act as a
tumor suppressor in early-stage PDAC development, by sustaining chro-
mosome stability and limiting pro-inﬂammatory nucleosome release
and activity in a K-ras-driven mouse model of PDAC [6]. On the ﬂip-
side, extracellular HGMB1 can act as a pro-tumor protein by enhancing,
for example, receptor for advanced glycation end products (RAGE)-de-
pendent inﬂammatory responses [7], and HGMB1 has also beenDOI of original article: https://doi.org/10.1016/j.ebiom.2018.12.016.
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While HMGB1 may likely have a dual role in tumor development,
and its pro- or anti-tumor properties may be tumor type speciﬁc, in
this study Cheng et al. highlight a previously undeﬁned and context-
speciﬁc role for this protein in PDAC and speciﬁcally in pancreatic
CSCs5. Following anti-cancer therapy, dying (necrotic or apoptotic)
cells are believed to secrete factors that can promote chemoresistance
or stimulate the regrowth of neighboring resident tumor cells. Cheng
and colleagues wisely associate radiotherapy-induced tumor cell
deathwith HMGB1 secretion and enrichment of the CD133+ pancreatic
CSC population. They provide, for the ﬁrst time, a mechanism by which
the “necrosis niche”, the intratumor microenvironment containing
dying cells, debris and their released soluble factors, can enrich for
CSCs following radiotherapy via secretedHMGB1. They show that radio-
therapy enriches for CD133+ CSCs from PDAC cell lines in vitro and
in vivo, dying cells secrete HMGB1, and secretedHMGB1or recombinant
HMGB1 can positively regulate CD133+ CSC in vitro stemness and
in vivo tumorigenicity via binding to TLR2, which is expressed to high
levels of CD133+ cells. HMGB1 can bind and activate TLR2, TLR4, and
TLR9, as well as RAGE, CD24 and certain integrins. Interestingly, the au-
thors observed that HMGB1 enrichment of CSCs was TLR2- and not
TLR4-speciﬁc as overexpression of TLR4, silencing of TLR4 or pharmaco-
logical inhibition of TLR4 revealed an unexpected antagonistic effect of
TLR4 on the HMGB1/TLR2 axis-induced stemness effect in CD133+
cells. It remains to be determined if TLR9, RAGE, CD24 or integrins are
also involved in this HMGB1-mediated pro-CSC signaling process.
Nonetheless, the authors were also able to show that the HMGB1/
TLR2 axis maintains and enhances the stemness of CD133+ CSCs by ac-
tivating Wnt/β-catenin signaling, highlighting several putative thera-
peutic targets.
Certainly, some pre-clinical and clinical aspects still remain
unresolved and should be further investigated in follow-up studies.
For example, while the in vivo studies inwhich CD133+ SW1990 cancer
cells were stimulated with conditioned media from irradiated
HMGB1+ cells, conditioned media from HMGB1-silenced cells or with
rhHMGB1 showed that HMGB1 can promote increased tumor growth
over 27 days, the use of K-ras-driven mouse models of PDAC with tem-
poral and conditional knockout of HMGB1 prior to irradiation may
provide more conclusive insights into the role HMGB1 in PDAC radio-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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HMGB1 expression, activity and release in a direct or indirect manner
for the treatment of cancer, as reviewed in [9]. For example, the
triterpenoid saponin glucoside of glycyrrhizic acid, Glycyrrhizin (GR),
can inhibit the chemotactic and mitogenic activities of HMGB1 [10],
and anti-HMGB1 antibodies could neutralize secreted HMGB1 in vivo.
The efﬁcacy of these and other HMGB1 inhibitors, alone or in combina-
tion with Wnt/β-catenin signaling inhibitors, should be tested in the
context of radiation therapy in vivo to conclusively determine the clini-
cal relevance of HMGB1 in pancreatic cancer radio-resistance. Never-
theless, this study offers a strong rational to continue investigating the
role of HMGB1 in PDAC, and provides important evidence to continue
elucidating how the “therapy-induced dying cell niche” may be more
harmful than helpful with respect to enriching or activating the CSC
compartment in PDAC.
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